Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 1/2 study of ifinatamab deruxtecan in relapsed or refractory solid tumors
NL-OMON61599Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in Nonhematologic neoplasms, osteosarcoma (OS), neuroblastoma and 2 more (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events in Part 1 and 4 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Nonhematologic neoplasmsosteosarcoma (OS)neuroblastomarhabdomyosarcoma (RMS)Wilms' tumor
Beyond the preview
Go deeper on NL-OMON61599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61599.